From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 2.24
Pain Relevance 0.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (FKBP1A) protein folding (FKBP1A) cytosol (FKBP1A)
signal transduction (FKBP1A) cytoplasm (FKBP1A) signal transducer activity (FKBP1A)
Anatomy Link Frequency
T cells 1
FKBP1A (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 3 78.96 Quite High
Bile 2 78.72 Quite High
analgesia 2 77.08 Quite High
opiate 9 76.52 Quite High
palliative 2 74.36 Quite High
Inflammation 25 69.44 Quite High
alcohol 2 68.32 Quite High
antagonist 12 61.20 Quite High
Breakthrough pain 1 58.20 Quite High
Bioavailability 12 57.32 Quite High
Disease Link Frequency Relevance Heat
Organ Transplantation 10 96.76 Very High Very High Very High
Apoptosis 5 96.60 Very High Very High Very High
Carcinoma 4 96.16 Very High Very High Very High
Renal Cell Carcinoma 29 95.00 High High
Cancer 107 94.36 High High
Retinoblastoma 1 91.12 High High
Body Weight 2 89.12 High High
Hyperplasia 6 88.20 High High
Cardiovascular Disease 46 82.72 Quite High
Sarcoma 8 81.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Both rapamycin and temsirolimus, a soluble ester analog of rapamycin, exert their action by binding to the intracellular protein, FKBP12, and inhibiting mTOR Complex 1 formation [38-40].
FKBP12 Binding (binding) of
1) Confidence 0.28 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.11 Pain Relevance 0.78
Everolimus (Afinitor®; RAD001; Novartis, USA) is an orally bioavailable mTOR inhibitor that binds with high affinity to its intracellular receptor FKBP12, at the same point in the mTOR pathway as temosirolimus.
FKBP12 Binding (binds) of
2) Confidence 0.25 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.49 Pain Relevance 0
It enters cells easily because of its lipophilic property and then binds to an intracellular receptor called FKBP12.
FKBP12 Binding (binds) of
3) Confidence 0.23 Published 2007 Journal McGill Journal of Medicine : MJM Section Body Doc Link PMC2323487 Disease Relevance 0.64 Pain Relevance 0.03
Rapamycin inhibits mTOR (via TORC1) following the formation of a complex with FKBP-12 [17].
FKBP-12 Binding (formation) of
4) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2882366 Disease Relevance 0.60 Pain Relevance 0
Despite the structural homology between sirolimus and tacrolimus with both drugs binding to the same intracellular immunophilin, FK506 binding protein, a 12-kDa binding protein (FK Binding protein-12) in T cells, the two drugs act synergistically rather than competitively and also differ in their mechanism of action.
FK506 binding protein Binding (binding) of in T cells
5) Confidence 0.02 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.20 Pain Relevance 0
The 50% inhibitory concentration for sirolimus inhibition of FK506 binding to FK506 binding protein 12 is approximately 0.4–0.9 nano moles per liter (nmol/L).
FK506 binding protein Binding (binding) of
6) Confidence 0.01 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.19 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools